Study of Malaria Treatment at Phuoc Long Hospital, Binh Phuoc Province, Vietnam

Malaria Clinical Trial

Official title:

Clinical Investigation of In-vivo Susceptibility of P. Falciparum to Artesunate in Phuoc Long Hospital, Binh Phuoc Province, Vietnam

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01165372
• Other study ID #: 02MA
• Status: Completed
• Phase: Phase 2
• First received: July 15, 2010
• Last updated: September 14, 2011
• Start date: August 2010
• Est. completion date: May 2011

Study information

• Verified date: September 2011
• Source: Oxford University Clinical Research Unit, Vietnam
• Contact: n/a
• Is FDA regulated: No
• Health authority: Viet Nam: Institute of Malaria, Parasitology and Entomology, Ho Chi Minh City
• Study type: Interventional

Clinical Trial Summary

Background: There are worrying signs from Western Cambodia that parasitological responses to artesunate containing treatment regimens for uncomplicated falciparum malaria are slower than elsewhere in the world. Delayed parasite clearance and unusually high failure rates with artesunate-mefloquine have been reported. These antimalarials are central to current treatment strategies and spread of significant resistance outside this area would be a global disaster. Radical containment measures are needed. In this context there is an urgent need to proceed quickly to investigate whether there is any evidence of resistance to artemisinin derivatives in Vietnam.

Objective: The primary objective is to assess the slope of the decline in the log parasitemia-time curve in patients treated with artesunate 2mg/kg/day, artesunate 4mg/kg/day or dihydroartemisinin-piperaquine once daily, and to compare the results of this study to the pharmacokinetic results and to the recent data from patients in Cambodia and Thailand treated with equivalent therapies.

Methods: The trial will be conducted in Phuoc Long Hospital, Binh Phuoc Province, Vietnam. The participants will be febrile patients (aged > 10 years) with slide confirmed uncomplicated P. falciparum infection. Patients will be treated with either artesunate 2mg/kg/day, artesunate 4mg/kg/day or dihydroartemisinin-piperaquine once daily for 3 days. Patients on artesunate therapy arms will then receive 3 days of treatment with dihydroartemisinin-piperaquine with dosages according to the national guidelines. Clinical and parasitological parameters will be monitored over a 42-day follow-up period. The pharmacokinetic characteristics of artesunate and dihydroartemisinin will be assessed by using a population pharmacokinetic modeling.

Description:

This surveillance study is a three-arm prospective evaluation of the efficacy of artesunate and dihydroartemisinin-piperaquine in acute uncomplicated falciparum malaria. This will be an evaluation of the slope of the decline in the log parasitemia-time curve, parasite clearance times in patients randomized to one of two different doses of oral artesunate or dihydroartemisinin-piperaquine. People with uncomplicated malaria who meet the study inclusion criteria will be enrolled, screened, randomized and treated on site with either artesunate 2mg/kg/day, artesunate 4mg/kg/day or dihydroartemisinin-piperaquine once daily according to weight for 3 days. The artesunate arms will immediately follow with dihydroartemisinin-piperaquine therapy for 3 days (study days 3 - 6) at the dose defined by national guidelines. Patients on all three arms will be monitored for 42 days. The follow-up will consist of a fixed schedule of check-up visits and corresponding clinical and laboratory examinations. PCR analysis will be used to distinguish between true recrudescence due to treatment failure and reinfection.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 166
• Est. completion date: May 2011
• Est. primary completion date: May 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 10 Years and older

Eligibility

Inclusion Criteria:

• male and aged > 10 years OR;

• female patients > 10 and <12 years old, provided they have not reached menarche

• mono-infection with P. falciparum detected by microscopy;

• parasitaemia of 10,000 - 100,000/µl asexual forms;

• presence of axillary or tympanic temperature = 37.5 °C or history of fever during the past 24 h;

• ability to swallow oral medication;

• ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule;

• informed consent/assent.

Exclusion Criteria:

• presence of general danger signs or severe falciparum malaria according to the definitions of WHO;

• mixed or mono-infection with another Plasmodium species detected by microscopy;

• presence of severe malnutrition (defined as a child whose growth standard is below -3 z-score, has symmetrical oedema involving at least the feet or has a mid-upper arm circumference < 110 mm);

• presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);

• regular medication, which may interfere with antimalarial pharmacokinetics;

• treatment with antimalarial drugs in the previous 48 hours;

• history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s);

• splenectomy.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Malaria

Intervention

Drug:
• Artesunate or dihydroartemisinin-piperaquine
artesunate 2mg/kg/day, artesunate 4mg/kg/day or dihydroartemisinin-piperaquine once daily

Locations

Country	Name	City	State
Vietnam	Phuoc Long Hospital	Dong Xoai	Binh Phuoc

Sponsors (2)

Lead Sponsor	Collaborator
Oxford University Clinical Research Unit, Vietnam	World Health Organization

Country where clinical trial is conducted

Vietnam, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Slope of the decline in the log parasitemia-time curve relative to historical data		03 days	No
Secondary	Clearance rate assessed from the fitted slope of the log-linear parasite curves		72 hours	No
Secondary	Proportion of patients who have a parasite clearance time >72 hours after initiation of each treatment		72 hours	No
Secondary	Parasitological efficacy of the three treatment arms		Over 72 hours and during follow-up treatment over a total follow-up period of 42 days	No
Secondary	Relative proportion of patients treated with artesunate 2mg/kg/day versus artesunate 4mg/kg/day versus dihydroartemisinin-piperaquine once daily	Patients who result as early treatment failures, late clinical failures, late parasitological failures or adequate clinical and parasitological response as indicators of efficacy	03 days	No
Secondary	Recrudescence and new infection rate defined by polymerase chain reaction (PCR) analysis between treatment arms		42 days	No
Secondary	Number of adverse events in each treatment arm		After initiation and during follow-up treatment over a total follow-up period of 42 days.	Yes
Secondary	Assess the pharmacokinetic characteristics of artesunate and dihydroartemisinin-piperaquine by using population pharmacokinetic modeling		03 days and upon relapse	No
Secondary	Characterize different genetic patterns from different resistant strains		03 days	No

External Links

•   Link